Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision: 10 days

Cancer Drug Resistance

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Articles

Most Recent | Most Viewed | Most Downloaded

Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers

Open Access Review DOI: 10.20517/cdr.2024.125 24 Jan 2025
Views: Downloads:
Download PDF

Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression

Open Access Review DOI: 10.20517/cdr.2024.169 21 Jan 2025
Views: Downloads:
Download PDF

Regulatory role of non-coding RNAs in 5-Fluorouracil resistance in gastrointestinal cancers

Open Access Review DOI: 10.20517/cdr.2024.167 15 Jan 2025
Views: Downloads:
Download PDF

Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma

Open Access Original Article DOI: 10.20517/cdr.2024.91 13 Jan 2025
Views: Downloads:
Download PDF

Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment

Open Access Review DOI: 10.20517/cdr.2024.152 6 Jan 2025
Views: Downloads:
Download PDF

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Open Access Review DOI: 10.20517/cdr.2023.16 19 Jun 2023
Views: Downloads:
Download PDF

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

Open Access Review DOI: 10.20517/cdr.2022.136 28 Apr 2023
Views: Downloads:
Download PDF

Anti-BCMA novel therapies for multiple myeloma

Open Access Review DOI: 10.20517/cdr.2022.138 21 Mar 2023
Views: Downloads:
Download PDF

Topic: Role of Tumor Microenvironment in Cancer Drug Resistance

Submission Deadline: 19 May 2025

Published articles: 3

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
We sincerely thank all reviewers for their dedication and expertise, essential to CDR's growth and cancer drug resistance research.
We invite exceptional young scholars to join us in advancing the field of cancer drug resistance and driving the next wave of scientific progress.
Cancer Drug Resistance has established a media partnership with EMBL Conference - Chromatin and epigenetics.
On November 4, 2024, the editorial team sat down with Prof. David A. Gewirtz, a leading scientist in oncology research and an esteemed member of the journal’s Editorial Board.
On September 16, 2024, Stanford University and Elsevier jointly released the list of the world’s top 2% scientists.

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Topic: Role of Tumor Microenvironment in Cancer Drug Resistance

Submission Deadline: 19 May 2025

Published articles: 3

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/